These and other findings have led to a “second hit” hypothesis, suggesting that another stressor in conjunction with severe deficiency of ADAMTS13 activity is usually required to develop clinical TTP [65,66]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.